Revolution Medicines (RVMD) Amortization of Deferred Charges (2021 - 2026)

Revolution Medicines' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 24.59% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 66.9% increase from a year earlier, with the FY2025 full-year figure at $7.9 million, up 88.47% from the prior year.
• Amortization of Deferred Charges slipped to $2.2 million in Q1 2026 per RVMD's latest filing, from $2.4 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $2.4 million in Q4 2025 and bottomed at $283000.0 in Q2 2023.
• The 5-year median for Amortization of Deferred Charges is $1.2 million (2022), against an average of $1.3 million.
• Across the five-year window, Amortization of Deferred Charges tumbled 75.09% in 2023 and jumped 213.78% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.2 million in 2022, then grew by 5.25% to $1.2 million in 2023, then advanced by 11.33% to $1.4 million in 2024, then surged by 70.83% to $2.4 million in 2025, then dropped by 7.48% to $2.2 million in 2026.
• Per Business Quant, the three latest RVMD Amortization of Deferred Charges figures stand at $2.2 million (Q1 2026), $2.4 million (Q4 2025), and $2.0 million (Q3 2025).